Breviscapine protects against cardiac hypertrophy through blocking PKC-α-dependent signaling

Journal of Cellular Biochemistry

Volumn 109, Issue 6, 2010, Pages 1158-1171

  Yan, Ling ^a,b   Huang, He ^a,b   Tang, Qi Zhu ^a,b   Zhu, Li Hua ^a,b   Wang, Lang ^a,b   Liu, Chen ^c   Bian, Zhou Yan ^a,b   Li, Hongliang ^a,b  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

Breviscapine; Cardiac hypertrophy; PKC ; SMAD

Indexed keywords

ANGIOTENSIN II; BREVISCAPINE; COLLAGEN; GLYCOGEN SYNTHASE KINASE 3BETA; LEUCINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE C ALPHA; TRITIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CHINESE MEDICINE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FIBROBLAST; GENE EXPRESSION; HEART HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART WEIGHT; HERBAL MEDICINE; HISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; BLOOD PRESSURE; BLOTTING, WESTERN; CARDIOMEGALY; CELLS, CULTURED; ECHOCARDIOGRAPHY; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FLAVONOIDS; GLYCOGEN SYNTHASE KINASE 3; MALE; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MYOCYTES, CARDIAC; PHOSPHORYLATION; PROTEIN KINASE C-ALPHA; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN;

MUS; RATTUS;

EID: 77951700259     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22495     Document Type: Article

References (41)

1. Baeuerle PA. 1998. IkappaB-NF-kappaB structures: At the interface of inflammation control. Cell 95:729-731. (Pubitemid 29014451)
2. Berk BC, Fujiwara K, Lehoux S. 2007. ECM remodeling in hypertensive heart disease. J Clin Invest 117:568-575. (Pubitemid 46348511)
3. Bian Z, Cai J, Shen DF, Chen L, Yan L, Tang Q, Li H. 2009. Cellular repressor of E1A-stimulated genes attenuates cardiac hypertrophy and fibrosis. J Cell Mol Med 13:1302-1313.
4. Braz JC, Bueno OF, De Windt LJ, Molkentin JD. 2002. PKC alpha regulates the hypertrophic growth of cardiomyocytes through extracellular signal-regulated kinase1/2 (ERK1/2). J Cell Biol 156:905-919.
5. Bueno OF, Molkentin JD. 2002. Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death. Circ Res 91: 776-781.
6. Cao W, Liu W, Wu T, Zhong D, Liu G. 2008. Dengzhanhua preparations for acute cerebral infarction. Cochrane Database Syst Rev CD005568.
7. Dorn GW II, Force T. 2005. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 115:527-537. (Pubitemid 40322222)
8. Epstein JA, Parmacek MS. 2005. Recent advances in cardiac development with therapeutic implications for adult cardiovascular disease. Circulation 112:592-597.
9. Fleegal MA, Sumners C. 2003. Angiotensin II induction of AP-1 in neurons requires stimulation of PI3-K and JNK. Biochem Biophys Res Commun 310:470-477. (Pubitemid 37163688)
10. Heineke J, Molkentin JD. 2006. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 7:589-600. (Pubitemid 44325350)
11. Jalili T, Takeishi Y, Walsh RA. 1999. Signal transduction during cardiac hypertrophy: The role of G alpha q, PLC beta I, and PKC. Cardiovasc Res 44: 5-9. (Pubitemid 29431677)
12. Kagiyama S, Eguchi S, Frank GD, Inagami T, Zhang YC, Phillips MI. 2002. Angiotensin II-induced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor receptor antisense. Circulation 106:909-912. (Pubitemid 34925322)
13. Kumar R, Singh VP, Baker KM. 2008. The intracellular renin-angiotensin system: Implications in cardiovascular remodeling. Curr Opin Nephrol Hypertens 17:168-173. (Pubitemid 351253042)
14. Li XL, Li YQ, Yan WM, Li HY, Xu H, Zheng XX, Guo DW, Tang LK. 2004. A study of the cardioprotective effect of breviscapine during hypoxia of cardiomyocytes. Planta Med 70:1039-1044.
15. Li HL, Wang AB, Huang Y, Liu DP, Wei C, Williams GM, Zhang CN, Liu G, Liu YQ, Hao DL, Hui RT, Lin M, Liang CC. 2005. Isorhapontigenin, a new resveratrol analog, attenuates cardiac hypertrophy via blocking signaling transduction pathways. Free Radic Biol Med 38:243-257. (Pubitemid 39656135)
16. Li HL, Huang Y, Zhang CN, Liu G, Wei YS, Wang AB, Liu YQ, Hui RT, Wei C, Williams GM, Liu DP, Liang CC. 2006. Epigallocathechin-3 gallate inhibits cardiac hypertrophy through blocking reactive oxidative species-dependent and -independent signal pathways. Free Radic Biol Med 40:1756-1775.
17. Li HL, She ZG, Li TB, Wang AB, Yang Q, Wei YS, Wang YG, Liu DP. 2007a. Overexpression of myofibrillogenesis regulator-1 aggravates cardiac hypertrophy induced by angiotensin II in mice. Hypertension 49:1399-1408. (Pubitemid 46809386)
18. Li HL, Zhuo ML, Wang D, Wang AB, Cai H, Sun LH, Yang Q, Huang Y, Wei YS, Liu PP, Liu DP, Liang CC. 2007b. Targeted cardiac overexpression of A20 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circulation 115:1885-1894. (Pubitemid 46598902)
19. Lin LL, Liu AJ, Liu JG, Yu XH, Qin LP, Su DF. 2007. Protective effects of scutellarin and breviscapine on brain and heart ischemia in rats. J Cardiovasc Pharmacol 50:327-332. (Pubitemid 47428983)
20. Luo P, Zhang Z, Yi T, Zhang H, Liu X, Mo Z. 2008. Anti-inflammatory activity of the extracts and fractions from Erigeron multiradiatus through bioassay-guided procedures. J Ethnopharmacol 119:232-237.
21. Nian M, Lee P, Khaper N, Liu P. 2004. Inflammatory cytokines and post myocardial infarction remodeling. Circ Res 94:1543-1553. (Pubitemid 38856961)
22. Pan J, Singh US, Takahashi T, Oka Y, Palm-Leis A, Herbelin BS, Baker KM. 2005. PKC mediates cyclic stretch-induced cardiac hypertrophy through Rho family GTPases and mitogen-activated protein kinases in cardiomyocytes. J Cell Physiol 202:536-553. (Pubitemid 40041325)
23. Pan Z, Feng T, Shan L, Cai B, Chu W, Niu H, Lu Y, Yang B. 2008. Scutellarin-induced endothelium-independent relaxation in rat aorta. Phytother Res 22:1428-1433. (Pubitemid 352789608)
24. Petrich BG, Wang Y. 2004. Stress-activated MAP kinases in cardiac remodeling and heart failure; New insights from transgenic studies. Trends Cardiovasc Med 14:50-55. (Pubitemid 38340846)
25. Proud CG. 2004. Ras, PI3-kinase and mTOR signaling in cardiac hypertrophy. Cardiovasc Res 63:403-413. (Pubitemid 38970184)
26. Reudelhuber TL, Bernstein KE, Delafontaine P. 2007. Is angiotensin II a direct mediator of left ventricular hypertrophy? Hypertension 49:1196-1201.
27. Rouet-Benzineb P, Gontero B, Dreyfus P, Lafuma C. 2000. Angiotensin II induces nuclear factor-kappa B activation in cultured neonatal rat cardiomyocytes through protein kinase C signaling pathway. J Mol Cell Cardiol 32:1767-1778.
28. Ruiz-Ortega M, Rodriguez-Vita J, Sanchez-Lopez E, Carvajal G, Egido J. 2007. TGF-beta signaling in vascular fibrosis. Cardiovasc Res 74:196-206.
29. Sadoshima J, Montagne O, Wang Q, Yang G, Warden J, Liu J, Takagi G, Karoor V, Hong C, Johnson GL, Vatner DE, Vatner SF. 2002. The MEKK1-JNK pathway plays a protective role in pressure overload but does not mediate cardiac hypertrophy. J Clin Invest 110:271-279. (Pubitemid 34787364)
30. Schonwasser DC, Marais RM, Marshall CJ, Parker PJ. 1998. Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes. Mol Cell Biol 18:790-798.
31. Shiojima I, Walsh K. 2006. Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway. Genes Dev 20:3347-3365. (Pubitemid 44969154)
32. Tang Q, Cai J, Shen D, Bian Z, Yan L, Wang YX, Lan J, Zhuang GQ, Ma WZ, Wang W. 2009. Lysosomal cysteine peptidase cathepsin L protects against cardiac hypertrophy through blocking AKT/GSK3beta signaling. J Mol Med 87:249-260.
33. Ueda Y, Hirai S, Osada S, Suzuki A, Mizuno K, Ohno S. 1996. Protein kinase C activates the MEK-ERK pathway in a manner independent of Ras and dependent on Raf. J Biol Chem 271:23512-23519. (Pubitemid 26314803)
34. Vijayan K, Szotek EL, Martin JL, Samarel AM. 2004. Protein kinase C-alpha-induced hypertrophy of neonatal rat ventricular myocytes. Am J Physiol Heart Circ Physiol 287:H2777-H2789. (Pubitemid 39557152)
35. Wu YG, Xia LL, Lin H, Zhou D, Qian H, Lin ST. 2007. Prevention of early liver injury by breviscapine in streptozotocin-induced diabetic rats. Planta Med 73:433-438. (Pubitemid 46917457)
36. Xiong Z, Liu C, Wang F, Li C, Wang W, Wang J, Chen J. 2006. Protective effects of breviscapine on ischemic vascular dementia in rats. Biol Pharm Bull 29:1880-1885. (Pubitemid 44338411)
37. Xu W, Zha RP, Wang WY, Wang YP. 2007. Effects of scutellarin on PKCgamma in PC12 cell injury induced by oxygen and glucose deprivation. Acta Pharmacol Sin 28:1573-1579. (Pubitemid 47493275)
38. Zhang SJ, Song Y, Zhai WL, Shi JH, Feng LS, Zhao YF, Chen S. 2007. Breviscapine alleviates hepatic injury and inhibits PKC-mRNA and its protein expression in brain-dead BA-Ma mini pigs. Hepatobiliary Pancreat Dis Int 6:604-609.
39. Zhou QS, Zhao YM, Bai X, Li PX, Ruan CG. 1992. Effect of new-breviscapine on fibrinolysis and anticoagulation of human vascular endothelial cells. Acta Pharmacol Sin 13:239-242.
40. Zhou J, Lei H, Chen Y, Li F, Ma C. 2002. Ventricular remodeling by Scutellarein treatment in spontaneously hypertensive rats. Chin Med J 115:375-377. (Pubitemid 34272436)
41. Zhu BH, Ma L, Pan XD, Huang YL, Liu J. 2008. Scutellarin induced Ca(2+) release and blocked KCl-induced Ca(2+) influx in smooth muscle cells isolated from rat thoracic artery. J Asian Nat Prod Res 10:583-589.